Inflarx (IFRX) Now Covered by Leerink Swann
Investment analysts at Leerink Swann started coverage on shares of Inflarx (NASDAQ:IFRX) in a research report issued on Monday, The Fly reports. The brokerage set an “outperform” rating on the stock.
Separately, J P Morgan Chase & Co initiated coverage on Inflarx in a report on Monday. They issued an “overweight” rating on the stock.
Inflarx (NASDAQ IFRX) opened at $20.88 on Monday. Inflarx has a 1-year low of $14.47 and a 1-year high of $22.48.
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company’s primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases.
Receive News & Ratings for Inflarx NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx NV and related companies with MarketBeat.com's FREE daily email newsletter.